# MOLCURE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molcure

- Industry: Biotechnology
- Headquarters: Kanagawa, Japan
- Website: http://molcure.com
- Total disclosed funding: $7.2M
- Latest round: Series C (Aug 18, 2021)
- Investors on record: 6

## About

MOLCURE Inc. is a Japan-based company focused on AI-driven molecular design, delivering advanced solutions to enhance drug discovery for pharmaceutical and biotechnology firms.Founded in 2013 and headquartered in Kanagawa, Japan, MOLCURE Inc. specializes in AI-driven molecular design. The company has successfully completed a total of 3 deals, with its most recent funding round, Series C, occurring on August 18, 2021. The firm raised JPY 790 million in this round from notable investors including JAFCO Group, Japan Post Capital, SBI Investment, and STRIVE. The CEO and founder, Ryu Ogawa, has a history of leadership in molecular design and innovation. The total amount raised by the company is JPY 790 million, reflecting their ongoing efforts in the biotechnology sector. The current company valuation stands at JPY 4,419.614 million.MOLCURE Inc. specializes in AI-driven molecular design, providing a suite of advanced technologies aimed at accelerating the drug discovery process. Their core offerings include an AI-powered de novo discovery platform, high-throughput screening capabilities, next-generation sequencing (NGS), and an AI-based lead optimization platform. These products are designed for pharmaceutical and biotechnology companies seeking to streamline their drug development efforts by discovering novel molecules, optimizing candidate molecules, and conducting comprehensive analyses of biological data. The company serves a diverse client base that includes researchers and pharmaceutical partners, predominantly in North America, Europe, and parts of Asia, who require innovative solutions to enhance their drug discovery processes.MOLCURE Inc. generates revenue through strategic partnerships and collaborations with pharmaceutical companies, providing services on a project basis or through ongoing consulting agreements. Their business model focuses on B2B transactions, delivering tailored solutions that may include subscriptions to their proprietary AI platforms and specialized project services. Revenue is derived from the deployment of their flagship products, such as the AI antibody discovery platform, which assists in molecular design and optimization. Clients typically engage in contracts that outline the scope of work and associated fees, reflecting the complexity and duration of the drug discovery initiatives being undertaken.Following their most recent funding round on August 18, 2021, where MOLCURE Inc. raised JPY 790 million, the company plans to accelerate joint development with major pharmaceutical companies and expand globally. They aim to enhance their business development efforts to improve quality of life (QOL) through innovative solutions. Specific markets targeted for growth include North America and Europe, with initiatives expected to roll out within the next two years.

## Funding rounds

- Series C, Aug 18, 2021, $7.2M — JAFCO Group, SBI Investment, GMO VenturePartners, STRIVE, Japan Post Capital, Nippon Chemiphar Company

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series C
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series C
- GMO VenturePartners (https://capitalatlas.ai/funds/gmo-venturepartners) — Series C
- STRIVE (https://capitalatlas.ai/funds/strive) — Series C
- Japan Post Capital (https://capitalatlas.ai/funds/japan-post-capital) — Series C
- Nippon Chemiphar Company — Series C